Aquestive Therapeutics Bolsa (NASDAQ: AQST)

Aquestive Therapeutics (NASDAQ:AQST) Bolsa

AQUESTIVE THERAPEUTICS INC

Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics Inc

News

DSGX

Descartes Systems Group Says Walking Comfort Boosts E-Commerce Efficiency With Descartes Sellercloud, Cuts Shipping Costs Over 55% And Saves Hundreds Of Hours Weekly

Rio Tinto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) and Hancock Prospecting have announced on Tuesday a joint investment of $1.61 billion to develop the Hope Downs 2 <a target="_blank" href="https://www.benzinga.com/topic/iron-ore" rel="noreferrer noopener">iron ore project</a> in Western Australia's Pilbara region. A 50-50 investment will drive a significant expansion of the long-standing Hope Downs Joint Venture between the two companies.
"Approval of Hope Downs 2 is a key milestone for Rio Tinto, as we invest in the next generation of iron ore mines in the Pilbara," Rio Tinto Iron Ore Chief Executive Simon Trott said in <a target="_blank" href="https://www.riotinto.com/en/news/releases/2025/rio-tinto-and-hancock-prospecting-to-invest-1-6-billion-to-develop-the-hope-downs-2-project-in-western-australias-pilbara" rel="noreferrer noopener">today's announcement</a>.
"These projects are part of our strategy to continue investing in Australian iron ore and to sustain Pilbara production for decades to come, supporting jobs, local businesses, and the state and national economies," he added.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45817251" rel="noreferrer noopener">Rio Tinto Opens $2B Pilbara Iron Ore Mine With China's Baowu</a>
The investment will fund the development of two new above-water-table iron ore pits at Hope Downs 2 and Bedded Hilltop. With a combined annual production capacity of 31 million tons, the new deposits will extend the life of the Hope Downs operations, which commenced in 2007. Ore from the new pits will be transported to the existing Hope Downs 1 processing facility. First ore is expected in 2027.
The project scope includes non-process infrastructure precincts, haul roads, rail crossings, and a realignment of a 6-kilometer stretch of the Great Northern Highway.
Rio Tinto's share in the $1.61 billion investment is part of a broader capital expenditure plan, with the miner intending to spend over $13 billion between 2025 and 2027 on new mines, equipment, and infrastructure.
"The Pilbara has been critical to global steel supply for more than 60 years, and we are committed to ensuring it remains so well into the future," Trott said.
Hope Downs 2 has secured all required State and Federal approvals. Rio Tinto has actively engaged with the Nyiyaparli, Banjima, and Ngarlawangga Peoples, as well as with government bodies, to manage heritage and environmental considerations.
The project is expected to create over 950 jobs during the construction phase and, once operational, approximately 1,000 full-time roles across the Greater Hope Downs complex.
Hope Downs 2 is part of Rio Tinto's broader plan to maintain a mid-term iron ore production capacity of 345 to 360 million tons per annum from its Pilbara operations. The company is also conducting a <a target="_blank" href="https://www.benzinga.com/news/management/25/05/45163353/rio-tinto-stops-activist-campaign-explores-critical-minerals-opportunities" rel="noreferrer noopener">pre-feasibility study</a> on the Rhodes Ridge project, one of the most promising undeveloped iron ore deposits in the region.
Still, according to the research firm BMI, the <a target="_blank" href="https://www.benzinga.com/25/03/44243837/iron-ore-production-to-accelerate-until-2030-study-says" rel="noreferrer noopener">long-term outlook</a> for iron ore is subdued. Prices are forecast to average $100 per ton in 2025 but are expected to decline to $78 per ton by 2034 gradually. While short-term demand from China remains resilient, BMI anticipates a structural shift in its economy toward less steel-intensive sectors and expects steady global supply growth to moderate prices over the next decade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/06/46047673/chevron-joins-lithium-race-with-125000-acre-texas-arkansas-deal" target="_blank" rel="noreferrer noopener">Chevron Joins Lithium Race With 125,000-Acre Texas-Arkansas Deal</a></li>
</ul>
Photo by Adwo via Shutterstock

Equities

Guidance

Financing

Commodities

Markets

Rio Tinto, Hancock Invest $1.6 Billion In Hope Downs 2 Expansion

Merck Says It Will Host HIV Research Pipeline Investor Event On July 17, 2025, Highlighting Advances In Treatment And Prevention

Castellum, Inc. (the "Company" and "Castellum") (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services and solutions company focused on the federal government, today announced the creation of a new wholly owned <a href="https://www.globenewswire.com/Tracker?data=PJ-JrOyhTdHSgPgEQtJRrDFk2Yt0JVWbP7AjyzFVlqn59aMMdjbPJBvIQ1cTN1miVyPsvXDz9yFe9Lh1nc2E4J69NnRrxaGYnT5kQ_MLLT0=">subsidiary</a>, Castellum Advanced Technology Products, Inc. ("CATP").
CATP will focus on teaming with other leading-edge technology companies, developing technology internally, and potentially taking equity positions in companies that have advanced technology, which Castellum's Department of Defense customers could use.

Castellum Creates New Wholly Owned Subsidiary, Castellum Advanced Technology Products, To Focus On Advanced Technology Products

Veeva Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NASDAQ">VEEV</a>) is currently in its 17th Phase of the 18-phase Adhishthana Cycle, and despite what may appear as bullish structure on the weekly charts, the best move for investors right now is to stay away. Here&#8217;s why.
<h3 class="wp-block-heading">Veev's Alignment So Far</h3>
Veev has shown strong historical alignment with Adhishthana Principles, our cyclical framework that integrates quantitative signals and proprietary behavioral archetypes. Some of the most notable phases include:
<h3 class="wp-block-heading">Phase 9: The Supreme Move</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="654" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24085541/Veev-Adhishthana-Himalayan-Formation.png" alt="Fig.1 Veev's Adhishthana Himalayan Formation (Source: Adhishthana.com)" class="wp-image-14798" style="width:657px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24085541/Veev-Adhishthana-Himalayan-Formation.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24085541/Veev-Adhishthana-Himalayan-Formation-300x164.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24085541/Veev-Adhishthana-Himalayan-Formation-1024x558.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24085541/Veev-Adhishthana-Himalayan-Formation-768x419.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 Veev&#8217;s Adhishthana Himalayan Formation (Source: Adhishthana.com)</figcaption></figure>
In line with the principle that Phase 9 represents the &#8220;Supreme Move&#8221;, Veev broke out of the Adhishthana Cakra formed between Phases 4 and 8, and rallied by a massive ~108%. This breakout rally also initiated the ascent of the Adhishthana Himalayan formation.
<h3 class="wp-block-heading">Phases 10 &amp; 11: Completion of the Himalayan Formation</h3>
Following the strong rally, Veev peaked in Phase 10, reaching an all-time high of $343.9, which perfectly matched the principles&#8217; call for a Himalayan peak in this phase. The descent began in Phase 11, again aligning with expectations, with the stock falling ~56%, retracing back to the origin point of its Phase 9 ascent.
<h3 class="wp-block-heading">Where We Are Now: Phase 17</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="613" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24085624/Veev-Guna-Triads-Adhishthana.png" alt="Fig.2 Veev's Guna Triads (Source: Adhishthana.com)" class="wp-image-14799" style="width:589px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24085624/Veev-Guna-Triads-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24085624/Veev-Guna-Triads-Adhishthana-300x153.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24085624/Veev-Guna-Triads-Adhishthana-1024x523.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24085624/Veev-Guna-Triads-Adhishthana-768x392.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.2 Veev&#8217;s Guna Triads (Source: Adhishthana.com)</figcaption></figure>
Veev is currently in Phase 17, classified in Adhishthana as a No-Action Phase. While rallies may occur during this phase, they are not meant to be chased.
The stock will enter Phase 18 on 15 Sep 2025, often considered the phase where a stock can reach Nirvana &#8211; its highest point in the 18-phase cycle. But here's the key problem: for a stock to reach Nirvana, the Guna Triads (Phases 14, 15, and 16) must exhibit Satoguna, or clean bullish energy.
In Veev's case, the Triads lacked Satoguna entirely, suggesting that the structure required to achieve Nirvana is missing. As a result, the stock is not expected to make a new all-time high in Phase 18, defying the typical pattern seen in successful cycles.
<h3 class="wp-block-heading">Monthly Chart Adds More Caution</h3>
Veev's monthly chart further validates the no-buy stance. The stock is in Phase 3, set to conclude on 31 Mar 2027. It will then enter Phase 4, another "No-Action" phase, lasting till 30 Sep 2030. That's a multi-year consolidation ahead.
In essence, both weekly and monthly timeframes point to the same conclusion: avoid chasing the current rally.
<h3 class="wp-block-heading">Investor Takeaway</h3>
The rally in Veev during Phase 17 is not sustainable within the Adhishthana framework. With no Satoguna in the Guna Triads and a lengthy no-action period ahead on the monthly chart, the likelihood of significant upside is low.
<ul class="wp-block-list">
<li>Current Longs: Consider trimming or hedging. </li>
<li>New Entries: Best postponed until a valid bullish structure re-emerges- likely years away. </li>
</ul>
<h3 class="wp-block-heading">Also Read:</h3>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46025785/marvell-technology-stock-levels-look-right-heres-what-to-watch">Marvell Technology: Stock Levels Look Right, Here&#8217;s What To Watch<span class="author" style="--tw-scale-x: 1;--tw-scale-y: 1;--tw-pan-x:;--tw-pan-y:;--tw-pinch-zoom:;--tw-scroll-snap-strictness: proximity;--tw-gradient-from-position:;--tw-gradient-via-position:;--tw-gradient-to-position:;--tw-ordinal:;--tw-slashed-zero:;--tw-numeric-figure:;--tw-numeric-spacing:;--tw-numeric-fraction:;--tw-ring-inset:;--tw-ring-offset-width: 0px;--tw-ring-offset-color: #fff;--tw-ring-offset-shadow: 0 0 #0000;--tw-ring-shadow: 0 0 #0000;--tw-shadow: 0 0 #0000;--tw-shadow-colored: 0 0 #0000;--tw-blur:;--tw-brightness:;--tw-contrast:;--tw-grayscale:;--tw-hue-rotate:;--tw-invert:;--tw-saturate:;--tw-sepia:;--tw-drop-shadow:;--tw-backdrop-blur:;--tw-backdrop-brightness:;--tw-backdrop-contrast:;--tw-backdrop-grayscale:;--tw-backdrop-hue-rotate:;--tw-backdrop-invert:;--tw-backdrop-opacity:;--tw-backdrop-saturate:;--tw-backdrop-sepia:;--tw-contain-size:;--tw-contain-layout:;--tw-contain-paint:;--tw-contain-style:"></a></li>
<li><a href="https://www.benzinga.com/markets/equities/25/06/46050199/is-roper-technologies-stock-signaling-a-peak">Is Roper Technologies Stock Signaling A Peak?</a></li>
</ul>

Technicals

Opinion

Signals

Trading Ideas

VEEV

Veeva's Rally Could Be A Bull Trap - A Prolonged Consolidation Looms

Tesla Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Chinese sales have gone down in the third week of June after experiencing steady growth in the country in May.
Check out the current price of <a href="https://benzinga.com/quote/tsla">TSLA stock here</a>.
What Happened: Tesla recorded over 13,800 new insured registrations in the Chinese domestic market for the week of June 16 to June 22, according to data shared by influencer Roland Pircher on X on Tuesday.
The registrations fell almost 11% compared to the previous week's 15,500 new registrations and almost 21% year-on-year. Data shared by Pircher also showcased that the company's sales went down 7.6% year-to-date.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">China reports 13.8k Tesla registrations for the week of June 16-22. &#x1f1e8;&#x1f1f3; The week is down 11.0% from last week and -20.7% year-over-year. The quarter is -5.4% QoQ and -17.1% YoY. This quarter is -38.2% vs. 24Q4 the best quarter after 12 weeks. YTD is at -7.6% YoY. Second highest… <a href="https://t.co/4OjhiE5VG1">pic.twitter.com/4OjhiE5VG1</a>
&mdash; Roland Pircher (@piloly) <a href="https://twitter.com/piloly/status/1937361140490580057?ref_src=twsrc%5Etfw">June 24, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The news comes in as Tesla had recently topped the sales charts in China with the company's <a href="https://www.benzinga.com/markets/tech/25/06/45855123/teslas-model-y-tops-china-suv-sales-chart-in-may-with-over-24700-cars-sold">Model Y emerging as the best-selling SUV</a> in the country during the month of May.
Tesla had also exported the <a href="https://www.benzinga.com/markets/asia/25/06/45834491/tesla-china-sales-surge-in-may-as-new-model-y-juniper-exported-for-the-first-time-amid-us-china-trade-war">Model Y Juniper out of China</a> for the first time recently and had registered over 38,588 units sold in May, which was a 34% increase compared to the previous month.
Elsewhere, Elon Musk's company had recently penned down a deal with the local government in Shanghai to set up a <a href="https://www.benzinga.com/markets/asia/25/06/46022846/elon-musks-tesla-to-build-first-grid-scale-energy-storage-site-in-china-with-550-million-investment">grid-scale energy storage</a> facility in the city with the company's Megapacks as part of a $550 million investment.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="200" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24053832/TSLA-JUN-24-2025-2-1024x200.jpg" alt="" class="wp-image-959477" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24053832/TSLA-JUN-24-2025-2-1024x200.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24053832/TSLA-JUN-24-2025-2-300x58.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24053832/TSLA-JUN-24-2025-2-768x150.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24053832/TSLA-JUN-24-2025-2-1536x300.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24053832/TSLA-JUN-24-2025-2.jpg 1559w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Tesla scores well on Momentum, Quality and Growth metrics, but offers poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge Stock Rankings</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46068107/elon-musks-tesla-faces-wrongful-death-lawsuit-over-model-s-crash-which-claimed-3-lives-plaintiffs-call-cars-design-defective-and-unreasonably-dangerous">Elon Musk&#8217;s Tesla Faces Wrongful Death Lawsuit Over Model S Crash Which Claimed 3 Lives: Plaintiffs Call Car&#8217;s Design &#8216;Defective And Unreasonably Dangerous&#8217;</a></li>
</ul>
Photo courtesy: Ken Wolter / Shutterstock.com

Tech

TSLA

Tesla's China Sales Slip Over 10% in Mid-June After Strong May Surge

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24083912/Cafe-De-Carol-1.jpeg" alt="" class="wp-image-14795" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24083912/Cafe-De-Carol-1.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24083912/Cafe-De-Carol-1-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24083912/Cafe-De-Carol-1-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The popular Hong Kong fast food chain's revenue, profit and gross margin all fell in its latest fiscal year, as it suffers from fundamental shifts in its home market

<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Café de Coral's revenue sagged 1.4% in its latest fiscal year, while its profit plunged nearly 30%</li>
<li>The popular Hong Kong fast food chain's gross margin also fell to 10.4% for the year, amid rapid changes on the city's dining scene</li>
</ul>
Café de Coral Holdings Ltd. (0341.HK) has been Hong Kong's dominant food chain for half a century, but its age is showing lately, as it fights to retain local diners in the face of a sluggish economy and changing dining trends.
The company's gloomy picture was on display for all to see earlier this month in its&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0616/2025061600149.pdf">latest financial report</a>&nbsp;that was hardly a feast for investor eyes. Its revenue declined 1.4% to HK$8.57 billion ($1.09 billion) in its latest fiscal year through March, while its profit sank 29.6% to HK$233 million. Even excluding fair-value losses related to property assets, the company's profit was still down 25.2% to HK$330 million. Café de Coral's gross profit margin also fell 1 percentage point to 10.4% during the year.
The company blamed the misery on an economic slowdown, as well as "weak consumer appetite, outbound travel and consumption of Hong Kong residents." It also pointed the finger at "intensifying price competition in the Mainland," a reference to Mainland China, where many of the company's customers are now flocking for weekend daytrips and getaways, drawing away one of its most important sources of business.
Investors could shrug off the weak year as just a blip on the radar, especially as Hong Kong's economy continues to suffer from a post-pandemic hangover. But what could be more worrisome is the possibility that the former Hong Kong king of casual dining, and its home restaurant market, are descending into a structural crisis.
<h4 class="wp-block-heading">Cross-border migration</h4>
Among the challenges facing Hong Kong, front and center is a growing trend to cross the Mainland border to Shenzhen for better and cheaper dining choices. Hundreds of thousands of Hong Kongers now make such trips on weekends and holidays, leaving less traffic for restaurants in Hong Kong. Instead of seeing a gradual return of diners as interest in such Mainland daytrips wanes, the situation has only gotten worse. Now, many residents are flocking even further into the Mainland, traveling not just to Shenzhen, but also other nearby cities like Zhuhai and Zhongshan.
Among other things, Mainland restaurants are generally more affordable to budget-conscious Hong Kong consumers. The Mainland's much larger land area also provides more diversified shopping opportunities and room for larger and more restaurants with lower rents. That contrasts sharply with Hong Kong restaurants, which are known for their limited space, prohibitive rents and higher prices.
Given such trends, an obvious solution for Café de Coral might be to follow the flow and set up more shops across the border to capture demand from wandering Hong Kong diners. But the fact is that such a move is easier said than done. While the Mainland market is huge and holds big potential for successful players, finding such success has been no easy matter for Hong Kong restaurants, including Café de Coral.
<h4 class="wp-block-heading">Earlier effort</h4>
In fact, Café de Coral is no stranger to the Mainland. It first set its sight on the market as early as 30 years ago but finally gave up after years of going nowhere. First it failed in Northern China, where tastes are quite different from those in its historic base in China's South. Later it also shuttered all its stores in Eastern China in 2017, leaving Hong Kong-adjacent Guangdong province as the only Mainland area where it maintained a presence.
Its downfall owed at least partly to its failure to cater to the palates of Mainland diners. While Hong Kong cuisine is known for being mostly light and mild, many Mainlanders enjoy variety in their diets and often prefer stronger and spicier flavors. The higher prices typically charged by foreign chains like Café de Coral also put off Mainland diners, who often tried out the chain and then never went back.
In an earlier era, Hong Kong chains could also take advantage of a slightly exotic aura among Mainland Chinese for anything associated with the former British colony. But those days are now long gone. As China's economy takes off and local consumers look farther afield for new and exotic flavors, their admiration for Hong Kong cuisine has rapidly faded, bringing another major barrier for Cafe de Coral in the Mainland market.
What's more, the conservative company, always protective of its profit margins, is hardly cut out to engage in the type of race-to-the-bottom cutthroat competition that repeatedly plays out on the Mainland. Many Mainland restaurant brands use a franchise model to give them thousands of shops across China. But most Cafe de Coral restaurants are self-operated, which naturally constrains its ability to expand and gain scale.
<h4 class="wp-block-heading">Rise of "two-dish meal boxes"</h4>
Its failure to crack the Mainland market aside, Café de Coral and its peers are also having to deal with structural shifts on Hong Kong's own dining scene. While fast food diners and traditional Hong Kong-style cafes were historically a go-to place for low-income residents, the rise of "two-dish meal boxes" is hitting both types of restaurants hard. Such boxes are mostly delivered on a takeout basis, making them cheaper by eliminating the need for physical dining spaces. The average two-dish meal box costs just over HK$40, or far less than traditional combo meals at low-end restaurants typically costing HK$60 to HK$70.
Local Hong Kong eateries have also had to contend with an influx of Mainland restaurant chains, including names like Tai Er Sauerkraut Fish, Baheli Beef Hot Pot, Muwu BBQ and Xiao Noodles. Those Chinese cousins are far more experienced at luring diners with low prices, sometimes selling below costs to outmaneuver their rivals. Such cutthroat new entrants could significantly erode Cafe de Coral's market share, adding to its investors' concerns.
In an earlier era when Hong Kong's economy boomed on its status as a window to China, well-managed local companies could always make it through the temporary downturn to prosper in the next boom cycle. But those days increasingly look like a thing of the past that's unlikely to return. With such major structural changes taking place all around it, Cafe de Coral's best days could well be behind it already.

Asia

Earnings

Cafe de Coral's Latest Financial Report: Hardly A Feast For Investors

On Monday, June 23, U.S. markets closed higher as investors were relieved by Iran&#8217;s measured response to American airstrikes, easing fears of wider conflict.
The major indexes ended higher, while oil prices plunged sharply after traders bet that global crude supplies would remain stable. Analysts pointed to Iran&#8217;s limited military capabilities and lack of strong allies as reasons for the market&#8217;s calm reaction despite heightened geopolitical risks in the Middle East.
In economic data, S&amp;P Global&#8217;s U.S. services PMI dipped to 53.1 in June from 53.7, slightly above expectations of 52.9. The manufacturing PMI remained unchanged at 52, indicating a steady expansion in factory activity.
Related: <a target="_blank" href="https://www.benzinga.com/news/events/25/06/46068524/israel-says-iran-broke-trump-ceasefire-orders-high-intensity-strikes-on-tehran" rel="noreferrer noopener">Israel Says Iran Broke Trump Ceasefire, Orders&#8217; High-Intensity Strikes&#8217; On Tehran</a>
Consumer and real estate stocks led broad S&amp;P 500 gains Monday, while energy shares fell as oil prices dropped.
The Dow rose 0.89% to 42,581.78, the S&amp;P 500 was up 0.96% to 6,025.17, and the Nasdaq gained 0.94% to 19,630.97.
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Tuesday, Japan&#8217;s Nikkei 225 closed 1.16% higher at 38,800.00, led by gains in the Real Estate, Banking, and Textile sectors.
Australia&#8217;s S&amp;P/ASX 200 was up 0.95% at 8,555.50, led by gains in the Metals &amp; Mining, Materials, and Financials sectors.
India&#8217;s Nifty 50 was up 0.26% at 25,037.10, and the Nifty 500 gained 0.48% to 23,110.60.
China&#8217;s Shanghai Composite was up 1.15% at 3,420.57, and Shanghai Shenzhen CSI 300 rose 1.20% to 3,904.03.
Hong Kong&#8217;s Hang Seng closed the session 2.06% higher at 24,177.07.
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was up 1.77%.
Germany&#8217;s DAX index gained 2.15%.
France&#8217;s CAC 40 rose 1.45%.
U.K.&#8217;s FTSE 100 index traded higher by 0.38%.
European shares jumped as Trump announced an Iran-Israel ceasefire, boosting travel stocks. Energy lagged on falling oil; the STOXX 600 rose, led by airlines and leisure.
<h2 class="wp-block-heading">Commodities</h2>
At 05:45 AM ET, the Crude Oil WTI was trading lower by 3.20% at $66.29/bbl, and Brent was down 3.29% at $68.21/bbl.
Oil prices dropped to two-week lows after Israel accepted Trump&#8217;s ceasefire plan with Iran, easing fears of supply disruption and erasing the recent risk premium in crude markets.
Natural gas fell 1.52% to $3.752.
Gold traded lower by 1.85% to $3,332.90, Silver slid 0.50% to $36.005, and Copper gained 0.87% to $4.8920.
<h2 class="wp-block-heading">U.S. Futures</h2>
At 05:45 AM ET, the Dow Jones futures rose 0.77%, the S&amp;P 500 gained 0.89%, and the Nasdaq 100 was up 1.17%.
<h2 class="wp-block-heading">Forex</h2>
At 05:45 AM ET, the U.S. Dollar Index declined 0.41% to 97.99, USD/JPY was down 0.81% to 144.97, and USD/AUD slid 0.78% to 1.5361.
The U.S. dollar fell as ceasefire optimism between Iran and Israel boosted risk appetite. The Dollar Index dropped while the euro, sterling, and yen gained on improving sentiment.
Photo via Shutterstock

Emerging Markets

Eurozone

Futures

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Global Markets Rally, Oil Plunges On Ceasefire Optimism

HCLTech Teams Up With AMD To Build Future-Ready Solutions Through AI-Powered Digital And Cloud Innovation

Shares of Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) rose sharply in today's pre-market trading after the company announced it will release top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational <a href="https://www.benzinga.com/quote/NKTR">rezpegaldesleukin on June 24, 2025</a>.
Nektar Therapeutics shares jumped 30.3% to $12.44 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>iBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) surged 55.8% to $1.11 in pre-market trading after the company announced it will host a conference call to review its advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.</li>
<li>Plus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) gained 27.7% to $0.2354 in pre-market trading after falling 5% on Monday.</li>
<li>Korea Electric Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEP#NYSE">KEP</a>) gained 20.1% to $12.44 in pre-market trading.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) rose 18.5% to $23.74 in pre-market trading after jumping over 38% on Monday.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) jumped 17.2% to $0.3089 in pre-market trading after gaining 7% on Monday. Adial Pharmaceuticals recently announced the pricing of a $3.6 million offering.</li>
<li>Surf Air Mobility Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NASDAQ">SRFM</a>) climbed 16.2% to $2.23 in pre-market trading.</li>
<li>Rezolve AI PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 11.8% to $2.28 in pre-market trading. Rezolve AI shares gained around 6% on Monday after the company announced it will join the Russell 2000 and Russell 3000 indexes</li>
<li>WF Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) rose 9.2% to $7.10 in pre-market trading after dipping 6% on Monday.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) gained 5.8% to $8.36 in pre-market trading. Teladoc shares surged over 14% on Monday after Citron Research made comments about the company on social media.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares tumbled 62.3% to $3.77 in pre-market trading after gaining 8% on Monday.</li>
<li>Maase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAAS#NASDAQ">MAAS</a>) shares fell 52.4% to $4.73 in pre-market trading after jumping over 268% on Monday.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) dipped 39.2% to $15.06 in pre-market trading. DeFi Development rescheduled release of shareholder letter and business update call to July.</li>
<li>Robin Energy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) declined 26.7% to $4.91 in pre-market trading after gaining 9% on Monday.</li>
<li>Indonesia Energy Corporation Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDO#NASDAQ">INDO</a>) dipped 25.4% to $3.64 in pre-market trading after falling around 4% on Monday.</li>
<li>TMD Energy Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#NYSE">TMDE</a>) fell 23.8% to $1.76 in pre-market trading after jumping 30% on Monday.</li>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) declined 22.1% to $1.16 in pre-market trading. Impact BioMedical shares jumped 345% on Monday after the company announced a limited merger and share exchange agreement with Dr Ashleys.</li>
<li>Nine Energy Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) fell 21.7% to $0.9160 in pre-market trading after jumping around 14% on Monday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 8.8% to $21.62 in pre-market trading after dipping 38% on Monday.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) fell 8.2% to $4.69 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

ADIL

DFDV

IBIO

INDO

LIMN

Highest Performances Holdings Inc. - American Depository Shares

MAAS

NINE

NKTR

PSTV

RBNE

RZLV

SRFM

TDOC

TMDE

UPXI

Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket

Verizon Unveils AI-Powered Customer Experience Overhaul Built On America's Fastest, Most Reliable 5G Network

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24083654/Nameson-0624-900x600-1.png" alt="" class="wp-image-14792" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24083654/Nameson-0624-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24083654/Nameson-0624-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24083654/Nameson-0624-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The apparel maker's revenue began to contract in the second half of its latest fiscal year, as business from its largest customer fell 11%
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Nameson's profit tumbled 40% in the second half of its latest fiscal year, as business from its largest customer fell and it spent heavily on a new production base in Vietnam</li>
<li>The company slashed its dividend for the second half of its fiscal year by more than half, citing its "ongoing commitment to prudent cash management"</li>
</ul>
The latest&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0620/2025062001312.pdf">annual results</a>&nbsp;from clothing maker&nbsp;Nameson Holdings Ltd.&nbsp;(1982.HK) are offering a complex patchwork of trends in the global apparel industry, from an economic slowdown dampening demand in China to the U.S.-China trade war that is pushing more manufacturing to Southeast Asia.
The bottom line for Nameson, both figuratively and literally, was an erosion of the company's business, resulting in tumbling profits in the second half of its fiscal year that runs through March 2025. The business declines were most notable in Japan and China, the company's top two markets, where sales during its latest fiscal year fell 19% and 7%, respectively, from the previous year.
Nameson's finances are also coming under pressure as it races to build up a production base in Vietnam, which it believes will be less affected than China by U.S. tariffs in Donald Trump's trade wars with the rest of the world. The company is also offering a lesson in some of the perils of geographic diversification, as it shifts production away from a facility in Myanmar due to customer requests and political instability in the Southeast Asian nation.
Investors haven't been too keen on apparel manufacturers for quite a while, and they weren't too excited about Nameson's latest report issued after the Hong Kong stock market closed last Friday. The stock fell 7.1% on Monday and is now down 8.2% so far this year. The shares trade at a price-to-earnings (P/E) ratio of just 5.3, roughly equal to&nbsp;Texhong's&nbsp;(2678.HK) 5.5, but well behind the 15 for&nbsp;Bosideng&nbsp;(3998.HK), a China-focused maker of winter apparel whose higher valuation derives from its well-known brand.
By comparison, names like Nameson and Texhong are largely anonymous, and instead they are making clothing for other big brand names. That difference is apparent in profit margins, with Nameson's gross margin of 18.0% for its latest fiscal year equal to less than half of Bosideng's 49.9% from its latest financial report for the six months through last September.
"The global economic landscape exhibited resilience despite facing challenges such as slower growth, persistent inflation, and policy uncertainties," Nameson said in its latest report. "Economic performance varied across countries, with spending behavior showing a complex recovery pattern."
While there was plenty of uncertainty around its business, one thing that was more certain was the company's decision to slash its dividend by more than half. Nameson actually raised its dividend slightly for the first half of its fiscal year to HK$0.098 per share from HK$0.095 the previous year. But in the latest report it slashed the dividend to just HK$0.015 for the second half of the year from HK$0.035 a year earlier.
It didn't directly address that decision but said in the report the company maintains an "ongoing commitment to prudent cash management, strong cash flow, and a healthy gearing ratio." The company's report shows that its cash tumbled 40% to HK$431 million ($55 million) by the end of March from HK$717 million a year earlier, and its gearing ratio more than doubled to 20.1% from 8.9% over that time.
While such trends certainly aren't cause for excitement, they also appear largely related to the company's aggressive expansion in Vietnam, which makes it look more proactive rather than fiscally irresponsible. At the end of the day, Nameson remains cash flow positive and profitable, even if its profits are coming under pressure.
<h4 class="wp-block-heading">Revenue contraction</h4>
While the diversification away from manufacturing in China looks prudent and like a good use of the company's financial resources, one thing that looks more worrisome is a sharp deterioration of Nameson's business in the second half of its latest fiscal year.
The latest report shows the company's revenue ticked down slightly, by less than 1%, to HK$4.35 billion for the 12 months through March from HK$4.38 billion in the previous year. But some calculations using data from the first half of the fiscal year show the company's revenue began to contract in the second of the year, falling by 5.3% after rising 2.2% in the first half.
The decline looks related to weakness in China and Japan, though the company didn't comment specifically on either market. But previous reports have indicated that Japanese fast fashion giant Uniqlo is Nameson's largest customer. Nameson's report says that revenue from its largest customer, which it didn't name, fell 11% in its latest fiscal year to HK$2.04 billion from HK$2.29 billion a year earlier, accounting for just over half of its revenue in the latest fiscal year.
The falling business from Uniqlo may represent weakness at the chain's China stores due to a slowing economy. But it's less clear why orders from its Japan operation fell so much, which may be one reason for investor concern. Whatever the reason, the drop may be partly responsible for a 33% rise in the company's inventory to HK$1.21 billion in the latest fiscal year from HK$911 million in the previous year.
The declines in China and Japan were partly offset by strength in Europe and North America, whose revenue for the year rose 21% to HK$833 million and 14% to HK$606 million, respectively. But as we've already noted, the North American business could come under pressure in the company's current fiscal year due to Donald Trump's tariffs on not only China, but also Vietnam.
Despite its declining revenue, Nameson did a good job controlling costs, and falling raw material costs helped it to improve its gross margin to 18.0% from 17.7% the previous year. On the bottom line, Nameson reported its full-year profit fell 5.4% to HK$342 million from HK$362 million the previous year. But calculations using data from the report for the first half of the fiscal year show the company's profit tumbled 40% in the second half of the year.
The bottom line is that Nameson is trying to diversify its production base to protect itself from the U.S.-China trade war, and is also learning about the dangers of relying too much on a single customer. We expect it will ultimately weather both storms, though its finances could get strained in that process, which will directly affect investors in the form of lower dividends.

Why Nameson's Profits Fell Sharply

&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4454704-1&amp;h=49307920&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>),&nbsp;a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today reported new long-term open-label extension (OLE) data from its phase 2 EMPhASIS trial of lead asset,&nbsp;orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS).
"It is meaningful to see that patients treated with vidofludimus calcium during the OLE period of our phase 2 EMPhASIS trial in RRMS experienced&nbsp;a low rate of confirmed disability worsening (CDW) events, as measured by the Expanded Disability Status Scale (EDSS). This data, representing approximately 952 treatment years, further underlines our belief that vidofludimus calcium holds great potential to&nbsp;effectively manage the disease, help preserve neurological function, allow patients to maintain independence and improve long-term quality of life," stated Andreas Muehler, M.D., M.B.A., Chief Medical Officer of Immunic.
The data at week 144 showed that 92.3% of patients remained free of 12-week CDW, and 92.7% free of 24-week CDW. A total of 29 CDW events were confirmed at 12 weeks following the trigger event through week 144. Of these, 44.8% were associated with relapse-associated worsening (RAW), while only 13.8% were associated with progression independent of relapse activity (PIRA). Additionally, the cumulative data available from the EMPhASIS OLE period, thus far, further reinforces the favorable safety and tolerability profile of vidofludimus calcium, showing low discontinuation rates and low rates of treatment-emergent and serious adverse events. Importantly,&nbsp;no new safety signals have emerged during treatment durations up to 5.5 years.
"This new data from the OLE period is very encouraging and continues to corroborate the prior strong results we observed in our phase 2 EMPhASIS trial in RRMS," stated Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. "The ability to maintain remarkably low rates of disability progression is among the most important unmet needs in relapsing MS despite the availability of multiple anti-inflammatory drugs approved for the treatment of MS relapses. By delaying disease progression, MS patients maintain greater independence, face a lower burden in managing their symptoms and experience more favorable long-term outcomes."
"Additionally, previously announced data across our multiple sclerosis (MS) program, including from the EMPhASIS trial as well as our recent top-line data from the phase 2 CALLIPER trial in progressive multiple sclerosis, has further highlighted vidofludimus calcium's&nbsp;potential to slow disease progression in MS and substantiated its neuroprotective capabilities through the activation of the Nurr1 target. As a reminder, despite 30-years of commercially available MS treatments, slowing and preventing disease progression still remains a critical unmet need. Based on the data we have generated, to date, we continue to believe that vidofludimus calcium, with its combined neuroprotective, anti-inflammatory and anti-viral effects as well as its established, highly favorable safety and tolerability profile, could represent a unique new oral therapy targeted to the complex pathophysiology of MS."
The phase 2 EMPhASIS trial was an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group study, designed to assess the efficacy and safety of vidofludimus calcium in patients with RRMS. The trial randomized 268 RRMS patients and included a 24-week blinded main treatment period testing 10, 30 and 45 mg of vidofludimus calcium and placebo. The trial achieved both primary and key secondary endpoints with high statistical significance and showed a favorable safety and tolerability profile similar to placebo. The trial includes an optional OLE period for up to 9.5 years to evaluate long-term safety and tolerability of vidofludimus calcium. Of the 268 patients that started the double-blind main treatment period, 254 patients continued in the OLE period. Patients were initially given&nbsp;either 30 mg or 45 mg of vidofludimus calcium once-daily,&nbsp;following which all patients received 30 mg of vidofludimus calcium once-daily.&nbsp;At the time of data cutoff on January 14, 2025, 182 patients (71.6% of patients starting OLE) were evaluated up to week 144, which translates into approximately 952 overall treatment years.

IMUX

Immunic Reports 92% of MS Patients Had No Disability Worsening After 3 Years on Lead Oral Drug

<ul>
<li>Aligned with FDA on&nbsp;NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the company plans to initiate a rolling NDA submission in July 2025 with target completion in the third quarter of 2025 &nbsp;</li>
<li>In 117 ROS1 TKI pre-treated patients, including 50% who had received ≥ 2 prior ROS1 TKIs ± chemotherapy, ORR by BICR was 44% (95% CI: 34, 53) with initial estimated durability of response of 78% at the 12-month landmark and 62% at the 18-month landmark &nbsp;</li>
<li>In the subset of 55 patients treated with 1 prior ROS1 TKI (crizotinib or entrectinib) ± chemotherapy, ORR was 51% (95% CI: 37, 65) with initial estimated durability of response of 93% at the 12- and 18-month landmarks &nbsp;</li>
<li>Zidesamtinib demonstrated intracranial responses, activity against tumors with a ROS1 G2032R resistance mutation, and a generally well-tolerated safety profile, including low rates of dose reduction (10%) and discontinuation (2%), consistent with its ROS1-selective, TRK-sparing design &nbsp;</li>
<li>Company announces progress in the front-line development strategies for its parallel lead programs in ROS1-positive and ALK-positive NSCLC &nbsp;</li>
<li>Company to host a conference call today, June 24th at 8:00am ET</li>
</ul>
CAMBRIDGE, Mass., June 24, 2025 /PRNewswire/ --&nbsp;<a href="https://www.nuvalent.com/">Nuvalent, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>), a clinical-stage biopharmaceutical company focused on creating&nbsp;precisely&nbsp;targeted therapies for clinically proven kinase targets in cancer, today announced positive pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) from the global ARROS-1 Phase 1/2 clinical trial.
In addition, Nuvalent announced progress on the front-line development strategies for its parallel lead programs in ROS1-positive and ALK-positive NSCLC, including:
<ul>
<li>The first report of preliminary data from the Phase 2 TKI-naïve cohort in its ARROS-1 clinical trial, in which global enrollment is ongoing; and,</li>
<li>The advancement of clinical startup activities to support the global initiation of the ALKAZAR Phase 3, randomized, controlled trial. The trial is designed to evaluate neladalkib, a novel ALK-selective inhibitor, versus alectinib, a front-line standard of care, for the treatment of patients with TKI-naïve ALK-positive NSCLC, and the company expects to begin enrollment early in the second half of 2025.</li>
</ul>
The company completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) and aligned on its plans to move forward with an NDA submission seeking an indication for the treatment of zidesamtinib for TKI pre-treated patients with locally advanced or metastatic ROS1-positive NSCLC. The FDA agreed to accept the NDA for participation in the Real-Time Oncology Review (RTOR) pilot program, which facilitates earlier submission of topline data to support an earlier start to the FDA's evaluation of the application. The company plans to initiate a rolling NDA submission in July 2025 with completion targeted for the third quarter of 2025, and continues to engage with the FDA on potential opportunities for line-agnostic expansion.

NUVL

Nuvalent Announces Pivotal Data For Zidesamtinib, ROS1-Selective Inhibitor, In TKI Pre-Treated Patients With Advanced ROS1-Positive NSCLC From Global ARROS-1 Phase 1/2 Clinical Trial

Zomedica Secures New US Patent For TRUVIEW Microscope, Expanding IP Portfolio To 221 Patents And 140 Trademarks

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4454481-1&amp;h=2584138876&amp;u=https%3A%2F%2Fwww.viavisolutions.com%2F&amp;a=VIAVI+Solutions+Inc.">VIAVI Solutions Inc.</a> (VIAVI) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) today announced that alternative network (Alt-Net) operator <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4454481-1&amp;h=1928996058&amp;u=https%3A%2F%2Fwww.netomnia.com%2F&amp;a=Netomnia">Netomnia</a>&nbsp;has chosen VIAVI's <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4454481-1&amp;h=3193763772&amp;u=https%3A%2F%2Fwww.viavisolutions.com%2Fen-us%2Fproducts%2Fonmsi-remote-fiber-test-system-rfts&amp;a=ONMSi+Remote+Fiber+Test+System+(RFTS)">ONMSi Remote Fiber Test System (RFTS)</a>&nbsp;to simplify and accelerate network installation and ongoing maintenance as the company rapidly expands&nbsp;its business in the UK.
&nbsp;
Netomnia, UK's second-largest Alt-Net,&nbsp;together with YouFibre and brsk, now has 2.5 million premises serviceable and 325,000 premises connected. With an annual build rate of one million premises, the group is poised to reach three million premises serviceable by end of 2025 with a new target of five million premises serviceable by the end of 2027.

VIAV

VIAVI Tapped by UK's Netomnia to Speed Up Fiber Rollout to 5 Million Homes by 2027

NUTX

Nutex Health Added To Russell 3000 Index And Russell Microcap Index, Effective June 30, As Part Of 2025 Russell Indexes Reconstitution

Kanzhun Launches Dual Listing Share Offer Of 30 Million Shares In Hong Kong And International Markets To Boost Flexibility And Investor Base

TRMB

Trimble And TDK Partner To Launch High-Precision Navigation Solution For Autonomous Vehicles, Drones, And Industrial IoT Applications

<ul>
<li>Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-months</li>
<li>Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II results are positive</li>
<li>U.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan drug designation, and Fast track designation</li>
<li>Laromestrocel HLHS program addresses unmet medical needs with U.S. market potential of up to $1 billion</li>
</ul>
MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LpTK0ohCzvSmm119iBVMPIVxBwZ0diUvbKgCWINgacLZ20PwHvC5wD8shoK1_ohH4Ag6He2-oYHxVyCsw8M5uW7Qb8DIjcevNN_kuFosDH4=">Longeveron Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has achieved full enrollment of the Phase 2b clinical trial (ELPIS II) evaluating its investigational cellular therapy <a href="https://www.globenewswire.com/Tracker?data=W1AagQaXvhI3pJkdhPX1jXyKjbyW6TncdwGjarjHlIAS0RuTYWORZfdmzd04rShPW7gXz_YUKmp10p_xLg4AgEHSwLmznqrgmcGrRvSvRdc=">laromestrocel</a> as a potential adjunct treatment for <a href="https://www.globenewswire.com/Tracker?data=hMHj6cUdu2hH5iyehQ_VyJEsbhtBqH6MUSxmYKMl-e6R_XzS4uCyyAp896RgWxkbiAvB3HDT7ri7qaHbAErr0_Dm8vqQqORlAuZ8QV5LjxPJ8aQC2D2fRn9lTe9XLIA2bpiV6LkVzqPjpWm4z_lQDQ==">Hypoplastic Left Heart Syndrome (HLHS)</a>, a rare pediatric and orphan-designated disease. Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-months. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated in multiple indications.

LGVN

Longeveron Completes Enrollment Of Phase 2b Clinical Trial Evaluating Investigational Cellular Therapy Laromestrocel As Potential Adjunct Treatment For Hypoplastic Left Heart Syndrome

Press Releases

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

Health Care

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions

Comments

Aquestive Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL